CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

July 16th, 2010

FDA reviewing link between ARBs and cancer

Last month a meta-analysis appearing in the Lancet found a modest but statistically significant increase in the risk of cancer associated with the use of angiotensin receptor blockers (ARBs).  On Thursday the FDA issued a safety communication and stated that it was conducting a review of ARBs. The FDA said that the review was ongoing and that it has not concluded that ARBs increase the risk of cancer, that it believes at this time the benefits of ARBs still outweigh the risks, and that it recommends that ARBs continue to be used as recommended in their approved labels.

Categories: General, Heart Failure


You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.